Epidiolex is a drug based on CBD. It is intended to be approved for use in rare forms of epilepsy. According to the Federal Register, the drug received a shedule V status.
The producer of Epidiolex had expected it to be included in shedule IV or better. But the DEA argued:
GW Pharma, which owns the rights to this pharmaceutical, wants to start selling immediately after these hurdles.